1054662-18-8

Basic information

• Product Name: 5-Isothiazol-5-yl-2-((E)-2-methyl-3-{(2S,3S,4R,5S)-5-[(2S,3S)-3-((1R,2S)-1-methyl-2-trimethylsilanyloxy-propyl)-oxiranylmethyl]-3,4-bis-trimethylsilanyloxy-tetrahydro-pyran-2-yl}-propenyl)-4-(toluene-4-sulfonyl)-4,5-dihydro-oxazole
• CAS NO: 1054662-18-8
• Molecular Weight: 823.307
• Mol File: 1054662-18-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-Isothiazol-5-yl-2-((E)-2-methyl-3-{(2S,3S,4R,5S)-5-[(2S,3S)-3-((1R,2S)-1-methyl-2-trimethylsilanyloxy-propyl)-oxiranylmethyl]-3,4-bis-trimethylsilanyloxy-tetrahydro-pyran-2-yl}-propenyl)-4-(toluene-4-sulfonyl)-4,5-dihydro-oxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Isothiazol-5-yl-2-((E)-2-methyl-3-{(2S,3S,4R,5S)-5-[(2S,3S)-3-((1R,2S)-1-methyl-2-trimethylsilanyloxy-propyl)-oxiranylmethyl]-3,4-bis-trimethylsilanyloxy-tetrahydro-pyran-2-yl}-propenyl)-4-(toluene-4-sulfonyl)-4,5-dihydro-oxazole(1054662-18-8)
• EPA Substance Registry System: 5-Isothiazol-5-yl-2-((E)-2-methyl-3-{(2S,3S,4R,5S)-5-[(2S,3S)-3-((1R,2S)-1-methyl-2-trimethylsilanyloxy-propyl)-oxiranylmethyl]-3,4-bis-trimethylsilanyloxy-tetrahydro-pyran-2-yl}-propenyl)-4-(toluene-4-sulfonyl)-4,5-dihydro-oxazole(1054662-18-8)

Safety Data

• Hazardous Substances Data: 1054662-18-8(Hazardous Substances Data)

Upstream product

• 5242-57-9 isothiazole-5-carboxaldehyde 
• 152366-36-4 monic acid, N-p-toluenesulphonylmethyl amide, tris(trimethylsilyl ether) 
• 66262-68-8 monic acid A 
• 133674-54-1 monic acid, tris(trimethylsilyl ether) 

Relevant articles and documents

The chemistry of pseudomonic acid part 14. Synthesis and in vivo biological activity of heterocyclyl substituted oxazole derivatives

Semisynthetic analogues of pseudomonic acid A have been prepared containing a heterocyclyl substituted oxazole. Derivatives in which the heterocycle was thiophene, furan, pyridine, or isoxazole showed good antibacterial potency and were further evaluated in vivo. Both pharmacokinetic parameters and oral activity against an experimental intraperitoneal sepsis were superior to results obtained from previously described pseudomonic acid A derivatives.